Book contents
- Frontmatter
- Contents
- List of contributors
- Acknowledgments
- Preface
- Part I General issues
- Part II Head and neck
- Part III Thorax
- Part IV Abdomen
- Part V Urology
- Part VI Oncology
- 57 Late effects of the treatment of childhood cancer
- 58 Neuroblastoma
- 59 Wilms' tumor
- 60 Rhabdomyosarcoma
- 61 Liver tumors and resections
- 62 Extragonadal germ cell tumors
- 63 Hemangiomas and vascular malformations
- Part VII Transplantation
- Part VIII Trauma
- Part IX Miscellaneous
- Index
- Plate section
- References
60 - Rhabdomyosarcoma
from Part VI - Oncology
Published online by Cambridge University Press: 08 January 2010
- Frontmatter
- Contents
- List of contributors
- Acknowledgments
- Preface
- Part I General issues
- Part II Head and neck
- Part III Thorax
- Part IV Abdomen
- Part V Urology
- Part VI Oncology
- 57 Late effects of the treatment of childhood cancer
- 58 Neuroblastoma
- 59 Wilms' tumor
- 60 Rhabdomyosarcoma
- 61 Liver tumors and resections
- 62 Extragonadal germ cell tumors
- 63 Hemangiomas and vascular malformations
- Part VII Transplantation
- Part VIII Trauma
- Part IX Miscellaneous
- Index
- Plate section
- References
Summary
Soft tissue sarcomas are the sixth most common malignancy of childhood, with rhabdomyosarcoma (RMS) by far the most frequent. In the United States, approximately 350 cases of RMS are diagnosed per year. Since 1975, the yearly incidence of RMS has remained stable at approximately 4 per 1 million children younger than 20 years of age.
Over the last 30 years, improved survival and decreased morbidity in treatment of RMS have been accomplished through collaborative clinical trials in both the United States and Europe. In the United States the Intergroup Rhabdomyosarcoma Study Group (IRSG) was established in 1972. Their mission has been to enroll all children diagnosed in North America into randomized prospective clinical trials. This has largely been accomplished with over 80% of North American children diagnosed with RMS enrolled in one of four completed IRSG studies. Since the inception of the IRSG, the overall survival for patients with RMS has improved from about 25% to over 70%. Much of this improvement has been the result of a multidisciplinary approach to rhabdomyosarcoma including surgeons, oncologists, and radiation oncologists. The IRSG (now called the Children's Oncology Group soft tissue sarcoma committee) continues to strive for improved survival with decreasing patient morbidity, and is currently accruing patients for its fifth trial (IRS-V).
Currently, orbital tumors have the best prognosis with a 5-year survival of approximately 95%.
- Type
- Chapter
- Information
- Pediatric Surgery and UrologyLong-Term Outcomes, pp. 782 - 798Publisher: Cambridge University PressPrint publication year: 2006